nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—Everolimus—kidney cancer	0.24	1	CrCtD
Temsirolimus—Protein Kinase Inhibitors—Sunitinib—kidney cancer	0.115	0.398	CiPCiCtD
Temsirolimus—Protein Kinase Inhibitors—Pazopanib—kidney cancer	0.0873	0.301	CiPCiCtD
Temsirolimus—Protein Kinase Inhibitors—Everolimus—kidney cancer	0.0873	0.301	CiPCiCtD
Temsirolimus—MTOR—kidney cancer	0.0846	0.854	CbGaD
Temsirolimus—MTOR—Everolimus—kidney cancer	0.0681	0.44	CbGbCtD
Temsirolimus—FKBP1A—Everolimus—kidney cancer	0.0588	0.38	CbGbCtD
Temsirolimus—Pimecrolimus—Everolimus—kidney cancer	0.0515	0.333	CrCrCtD
Temsirolimus—Sirolimus—Everolimus—kidney cancer	0.0515	0.333	CrCrCtD
Temsirolimus—Tacrolimus—Everolimus—kidney cancer	0.0515	0.333	CrCrCtD
Temsirolimus—ABCB1—kidney cancer	0.0145	0.147	CbGaD
Temsirolimus—CYP3A4—Everolimus—kidney cancer	0.00167	0.0108	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.00132	0.00854	CbGbCtD
Temsirolimus—CYP3A7—Paclitaxel—kidney cancer	0.00132	0.00854	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.00117	0.00759	CbGbCtD
Temsirolimus—CYP3A7—Sorafenib—kidney cancer	0.00117	0.00759	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.00114	0.00737	CbGbCtD
Temsirolimus—CYP3A7—Vincristine—kidney cancer	0.00114	0.00737	CbGbCtD
Temsirolimus—CYP3A5—Erlotinib—kidney cancer	0.00108	0.007	CbGbCtD
Temsirolimus—CYP3A5—Paclitaxel—kidney cancer	0.000991	0.00641	CbGbCtD
Temsirolimus—ABCB1—Pazopanib—kidney cancer	0.000987	0.00639	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.000951	0.00615	CbGbCtD
Temsirolimus—CYP3A7—Sunitinib—kidney cancer	0.000951	0.00615	CbGbCtD
Temsirolimus—CYP2D6—Pazopanib—kidney cancer	0.00093	0.00602	CbGbCtD
Temsirolimus—ABCB1—Dactinomycin—kidney cancer	0.000903	0.00584	CbGbCtD
Temsirolimus—CYP3A5—Sorafenib—kidney cancer	0.00088	0.00569	CbGbCtD
Temsirolimus—CYP3A5—Vincristine—kidney cancer	0.000854	0.00553	CbGbCtD
Temsirolimus—ABCB1—Gemcitabine—kidney cancer	0.000714	0.00462	CbGbCtD
Temsirolimus—CYP3A5—Sunitinib—kidney cancer	0.000713	0.00461	CbGbCtD
Temsirolimus—ABCB1—Erlotinib—kidney cancer	0.000704	0.00456	CbGbCtD
Temsirolimus—CYP2D6—Erlotinib—kidney cancer	0.000664	0.00429	CbGbCtD
Temsirolimus—ABCB1—Paclitaxel—kidney cancer	0.000645	0.00417	CbGbCtD
Temsirolimus—CYP3A4—Pazopanib—kidney cancer	0.000591	0.00383	CbGbCtD
Temsirolimus—ABCB1—Sorafenib—kidney cancer	0.000573	0.00371	CbGbCtD
Temsirolimus—ABCB1—Vinblastine—kidney cancer	0.000566	0.00366	CbGbCtD
Temsirolimus—ABCB1—Vincristine—kidney cancer	0.000556	0.0036	CbGbCtD
Temsirolimus—CYP2D6—Sorafenib—kidney cancer	0.00054	0.00349	CbGbCtD
Temsirolimus—CYP2D6—Vinblastine—kidney cancer	0.000533	0.00345	CbGbCtD
Temsirolimus—ABCB1—Sunitinib—kidney cancer	0.000464	0.003	CbGbCtD
Temsirolimus—CYP3A4—Erlotinib—kidney cancer	0.000422	0.00273	CbGbCtD
Temsirolimus—CYP3A4—Paclitaxel—kidney cancer	0.000386	0.0025	CbGbCtD
Temsirolimus—ABCB1—Doxorubicin—kidney cancer	0.000348	0.00225	CbGbCtD
Temsirolimus—CYP3A4—Sorafenib—kidney cancer	0.000343	0.00222	CbGbCtD
Temsirolimus—CYP3A4—Vinblastine—kidney cancer	0.000339	0.00219	CbGbCtD
Temsirolimus—CYP3A4—Vincristine—kidney cancer	0.000333	0.00216	CbGbCtD
Temsirolimus—CYP2D6—Doxorubicin—kidney cancer	0.000327	0.00212	CbGbCtD
Temsirolimus—Everolimus—MTOR—kidney cancer	0.000305	0.295	CrCbGaD
Temsirolimus—Pimecrolimus—MTOR—kidney cancer	0.000305	0.295	CrCbGaD
Temsirolimus—CYP3A4—Sunitinib—kidney cancer	0.000278	0.0018	CbGbCtD
Temsirolimus—CYP3A4—urine—kidney cancer	0.000256	0.0793	CbGeAlD
Temsirolimus—CYP2D6—urine—kidney cancer	0.000252	0.0781	CbGeAlD
Temsirolimus—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.000222	0.0687	CbGeAlD
Temsirolimus—MTOR—renal system—kidney cancer	0.000213	0.066	CbGeAlD
Temsirolimus—CYP3A4—Doxorubicin—kidney cancer	0.000208	0.00135	CbGbCtD
Temsirolimus—MTOR—kidney—kidney cancer	0.000206	0.0638	CbGeAlD
Temsirolimus—FKBP1A—renal system—kidney cancer	0.000191	0.0594	CbGeAlD
Temsirolimus—MTOR—gonad—kidney cancer	0.000191	0.0592	CbGeAlD
Temsirolimus—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.00019	0.0588	CbGeAlD
Temsirolimus—FKBP1A—kidney—kidney cancer	0.000185	0.0574	CbGeAlD
Temsirolimus—Tacrolimus—MTOR—kidney cancer	0.000181	0.175	CrCbGaD
Temsirolimus—Sirolimus—MTOR—kidney cancer	0.000181	0.175	CrCbGaD
Temsirolimus—FKBP1A—cortex of kidney—kidney cancer	0.00018	0.0559	CbGeAlD
Temsirolimus—FKBP1A—gonad—kidney cancer	0.000172	0.0533	CbGeAlD
Temsirolimus—FKBP1A—cardiac atrium—kidney cancer	0.000171	0.0532	CbGeAlD
Temsirolimus—CYP3A5—nephron tubule—kidney cancer	9.17e-05	0.0285	CbGeAlD
Temsirolimus—CYP3A5—renal system—kidney cancer	8.34e-05	0.0259	CbGeAlD
Temsirolimus—CYP3A5—kidney—kidney cancer	8.06e-05	0.025	CbGeAlD
Temsirolimus—CYP3A5—cortex of kidney—kidney cancer	7.85e-05	0.0244	CbGeAlD
Temsirolimus—CYP3A4—renal system—kidney cancer	6.26e-05	0.0194	CbGeAlD
Temsirolimus—CYP2D6—renal system—kidney cancer	6.16e-05	0.0191	CbGeAlD
Temsirolimus—CYP3A4—kidney—kidney cancer	6.05e-05	0.0188	CbGeAlD
Temsirolimus—CYP2D6—kidney—kidney cancer	5.95e-05	0.0185	CbGeAlD
Temsirolimus—ABCB1—nephron tubule—kidney cancer	4.87e-05	0.0151	CbGeAlD
Temsirolimus—ABCB1—renal system—kidney cancer	4.43e-05	0.0137	CbGeAlD
Temsirolimus—ABCB1—kidney—kidney cancer	4.28e-05	0.0133	CbGeAlD
Temsirolimus—ABCB1—cortex of kidney—kidney cancer	4.17e-05	0.0129	CbGeAlD
Temsirolimus—ABCB1—gonad—kidney cancer	3.97e-05	0.0123	CbGeAlD
Temsirolimus—Sirolimus—ABCB1—kidney cancer	3.11e-05	0.0301	CrCbGaD
Temsirolimus—Tacrolimus—ABCB1—kidney cancer	3.11e-05	0.0301	CrCbGaD
Temsirolimus—Anaemia—Paclitaxel—kidney cancer	1.12e-05	0.000273	CcSEcCtD
Temsirolimus—Urethral disorder—Capecitabine—kidney cancer	1.12e-05	0.000273	CcSEcCtD
Temsirolimus—Dermatitis bullous—Doxorubicin—kidney cancer	1.11e-05	0.000271	CcSEcCtD
Temsirolimus—Rash—Everolimus—kidney cancer	1.11e-05	0.000271	CcSEcCtD
Temsirolimus—Dermatitis—Everolimus—kidney cancer	1.11e-05	0.000271	CcSEcCtD
Temsirolimus—Headache—Vinblastine—kidney cancer	1.11e-05	0.00027	CcSEcCtD
Temsirolimus—Angioedema—Paclitaxel—kidney cancer	1.11e-05	0.00027	CcSEcCtD
Temsirolimus—Headache—Everolimus—kidney cancer	1.1e-05	0.000269	CcSEcCtD
Temsirolimus—Abdominal pain—Dactinomycin—kidney cancer	1.1e-05	0.000269	CcSEcCtD
Temsirolimus—Body temperature increased—Dactinomycin—kidney cancer	1.1e-05	0.000269	CcSEcCtD
Temsirolimus—Asthenia—Sorafenib—kidney cancer	1.1e-05	0.000268	CcSEcCtD
Temsirolimus—Leukopenia—Paclitaxel—kidney cancer	1.09e-05	0.000264	CcSEcCtD
Temsirolimus—Hypersensitivity—Sunitinib—kidney cancer	1.08e-05	0.000264	CcSEcCtD
Temsirolimus—Decreased appetite—Vincristine—kidney cancer	1.08e-05	0.000264	CcSEcCtD
Temsirolimus—Pruritus—Sorafenib—kidney cancer	1.08e-05	0.000264	CcSEcCtD
Temsirolimus—Vomiting—Erlotinib—kidney cancer	1.08e-05	0.000264	CcSEcCtD
Temsirolimus—Erythema multiforme—Capecitabine—kidney cancer	1.08e-05	0.000263	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Gemcitabine—kidney cancer	1.08e-05	0.000262	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Vincristine—kidney cancer	1.08e-05	0.000262	CcSEcCtD
Temsirolimus—Fatigue—Vincristine—kidney cancer	1.07e-05	0.000262	CcSEcCtD
Temsirolimus—Rash—Erlotinib—kidney cancer	1.07e-05	0.000261	CcSEcCtD
Temsirolimus—Dermatitis—Erlotinib—kidney cancer	1.07e-05	0.000261	CcSEcCtD
Temsirolimus—Insomnia—Gemcitabine—kidney cancer	1.07e-05	0.00026	CcSEcCtD
Temsirolimus—Eye disorder—Capecitabine—kidney cancer	1.07e-05	0.00026	CcSEcCtD
Temsirolimus—Headache—Erlotinib—kidney cancer	1.07e-05	0.00026	CcSEcCtD
Temsirolimus—Pain—Vincristine—kidney cancer	1.07e-05	0.00026	CcSEcCtD
Temsirolimus—Constipation—Vincristine—kidney cancer	1.07e-05	0.00026	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	1.06e-05	0.000259	CcSEcCtD
Temsirolimus—Cardiac disorder—Capecitabine—kidney cancer	1.06e-05	0.000258	CcSEcCtD
Temsirolimus—Cough—Paclitaxel—kidney cancer	1.06e-05	0.000258	CcSEcCtD
Temsirolimus—Asthenia—Sunitinib—kidney cancer	1.06e-05	0.000257	CcSEcCtD
Temsirolimus—Dyspnoea—Gemcitabine—kidney cancer	1.05e-05	0.000257	CcSEcCtD
Temsirolimus—Nausea—Vinblastine—kidney cancer	1.05e-05	0.000256	CcSEcCtD
Temsirolimus—Somnolence—Gemcitabine—kidney cancer	1.05e-05	0.000256	CcSEcCtD
Temsirolimus—Convulsion—Paclitaxel—kidney cancer	1.05e-05	0.000256	CcSEcCtD
Temsirolimus—Nausea—Everolimus—kidney cancer	1.05e-05	0.000255	CcSEcCtD
Temsirolimus—Diarrhoea—Sorafenib—kidney cancer	1.05e-05	0.000255	CcSEcCtD
Temsirolimus—Hypertension—Paclitaxel—kidney cancer	1.05e-05	0.000255	CcSEcCtD
Temsirolimus—Pruritus—Sunitinib—kidney cancer	1.04e-05	0.000254	CcSEcCtD
Temsirolimus—Angiopathy—Capecitabine—kidney cancer	1.04e-05	0.000253	CcSEcCtD
Temsirolimus—Immune system disorder—Capecitabine—kidney cancer	1.03e-05	0.000252	CcSEcCtD
Temsirolimus—Arthralgia—Paclitaxel—kidney cancer	1.03e-05	0.000251	CcSEcCtD
Temsirolimus—Chest pain—Paclitaxel—kidney cancer	1.03e-05	0.000251	CcSEcCtD
Temsirolimus—Myalgia—Paclitaxel—kidney cancer	1.03e-05	0.000251	CcSEcCtD
Temsirolimus—Mediastinal disorder—Capecitabine—kidney cancer	1.03e-05	0.000251	CcSEcCtD
Temsirolimus—Anxiety—Paclitaxel—kidney cancer	1.03e-05	0.000251	CcSEcCtD
Temsirolimus—Face oedema—Doxorubicin—kidney cancer	1.03e-05	0.00025	CcSEcCtD
Temsirolimus—Decreased appetite—Gemcitabine—kidney cancer	1.03e-05	0.00025	CcSEcCtD
Temsirolimus—Hypersensitivity—Dactinomycin—kidney cancer	1.03e-05	0.00025	CcSEcCtD
Temsirolimus—Chills—Capecitabine—kidney cancer	1.03e-05	0.00025	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	1.02e-05	0.00025	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Gemcitabine—kidney cancer	1.02e-05	0.000249	CcSEcCtD
Temsirolimus—Fatigue—Gemcitabine—kidney cancer	1.02e-05	0.000248	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Vincristine—kidney cancer	1.02e-05	0.000248	CcSEcCtD
Temsirolimus—Dizziness—Sorafenib—kidney cancer	1.01e-05	0.000247	CcSEcCtD
Temsirolimus—Constipation—Gemcitabine—kidney cancer	1.01e-05	0.000246	CcSEcCtD
Temsirolimus—Pain—Gemcitabine—kidney cancer	1.01e-05	0.000246	CcSEcCtD
Temsirolimus—Nausea—Erlotinib—kidney cancer	1.01e-05	0.000246	CcSEcCtD
Temsirolimus—Diarrhoea—Sunitinib—kidney cancer	1.01e-05	0.000246	CcSEcCtD
Temsirolimus—Mental disorder—Capecitabine—kidney cancer	1e-05	0.000244	CcSEcCtD
Temsirolimus—Asthenia—Dactinomycin—kidney cancer	1e-05	0.000244	CcSEcCtD
Temsirolimus—Blood creatinine increased—Doxorubicin—kidney cancer	9.97e-06	0.000243	CcSEcCtD
Temsirolimus—Erythema—Capecitabine—kidney cancer	9.95e-06	0.000242	CcSEcCtD
Temsirolimus—Malnutrition—Capecitabine—kidney cancer	9.95e-06	0.000242	CcSEcCtD
Temsirolimus—Dehydration—Doxorubicin—kidney cancer	9.9e-06	0.000241	CcSEcCtD
Temsirolimus—Anaphylactic shock—Paclitaxel—kidney cancer	9.89e-06	0.000241	CcSEcCtD
Temsirolimus—Oedema—Paclitaxel—kidney cancer	9.89e-06	0.000241	CcSEcCtD
Temsirolimus—Abdominal pain—Vincristine—kidney cancer	9.85e-06	0.00024	CcSEcCtD
Temsirolimus—Body temperature increased—Vincristine—kidney cancer	9.85e-06	0.00024	CcSEcCtD
Temsirolimus—Infection—Paclitaxel—kidney cancer	9.83e-06	0.00024	CcSEcCtD
Temsirolimus—Dry skin—Doxorubicin—kidney cancer	9.76e-06	0.000238	CcSEcCtD
Temsirolimus—Dysgeusia—Capecitabine—kidney cancer	9.74e-06	0.000237	CcSEcCtD
Temsirolimus—Dizziness—Sunitinib—kidney cancer	9.74e-06	0.000237	CcSEcCtD
Temsirolimus—Vomiting—Sorafenib—kidney cancer	9.73e-06	0.000237	CcSEcCtD
Temsirolimus—Nervous system disorder—Paclitaxel—kidney cancer	9.7e-06	0.000236	CcSEcCtD
Temsirolimus—Hypokalaemia—Doxorubicin—kidney cancer	9.69e-06	0.000236	CcSEcCtD
Temsirolimus—Thrombocytopenia—Paclitaxel—kidney cancer	9.69e-06	0.000236	CcSEcCtD
Temsirolimus—Rash—Sorafenib—kidney cancer	9.65e-06	0.000235	CcSEcCtD
Temsirolimus—Dermatitis—Sorafenib—kidney cancer	9.64e-06	0.000235	CcSEcCtD
Temsirolimus—Back pain—Capecitabine—kidney cancer	9.62e-06	0.000234	CcSEcCtD
Temsirolimus—Skin disorder—Paclitaxel—kidney cancer	9.61e-06	0.000234	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	9.59e-06	0.000234	CcSEcCtD
Temsirolimus—Headache—Sorafenib—kidney cancer	9.59e-06	0.000234	CcSEcCtD
Temsirolimus—Diarrhoea—Dactinomycin—kidney cancer	9.54e-06	0.000232	CcSEcCtD
Temsirolimus—Anorexia—Paclitaxel—kidney cancer	9.43e-06	0.00023	CcSEcCtD
Temsirolimus—Gastritis—Doxorubicin—kidney cancer	9.42e-06	0.00023	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Doxorubicin—kidney cancer	9.39e-06	0.000229	CcSEcCtD
Temsirolimus—Vomiting—Sunitinib—kidney cancer	9.36e-06	0.000228	CcSEcCtD
Temsirolimus—Body temperature increased—Gemcitabine—kidney cancer	9.34e-06	0.000228	CcSEcCtD
Temsirolimus—Rash—Sunitinib—kidney cancer	9.29e-06	0.000226	CcSEcCtD
Temsirolimus—Dermatitis—Sunitinib—kidney cancer	9.28e-06	0.000226	CcSEcCtD
Temsirolimus—Abdominal distension—Doxorubicin—kidney cancer	9.26e-06	0.000226	CcSEcCtD
Temsirolimus—Headache—Sunitinib—kidney cancer	9.23e-06	0.000225	CcSEcCtD
Temsirolimus—Dysphagia—Doxorubicin—kidney cancer	9.2e-06	0.000224	CcSEcCtD
Temsirolimus—Influenza—Doxorubicin—kidney cancer	9.2e-06	0.000224	CcSEcCtD
Temsirolimus—Anaemia—Capecitabine—kidney cancer	9.19e-06	0.000224	CcSEcCtD
Temsirolimus—Hypersensitivity—Vincristine—kidney cancer	9.18e-06	0.000224	CcSEcCtD
Temsirolimus—Nausea—Sorafenib—kidney cancer	9.09e-06	0.000222	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Paclitaxel—kidney cancer	9.01e-06	0.00022	CcSEcCtD
Temsirolimus—Insomnia—Paclitaxel—kidney cancer	8.95e-06	0.000218	CcSEcCtD
Temsirolimus—Asthenia—Vincristine—kidney cancer	8.94e-06	0.000218	CcSEcCtD
Temsirolimus—Leukopenia—Capecitabine—kidney cancer	8.9e-06	0.000217	CcSEcCtD
Temsirolimus—Vomiting—Dactinomycin—kidney cancer	8.86e-06	0.000216	CcSEcCtD
Temsirolimus—Bronchitis—Doxorubicin—kidney cancer	8.85e-06	0.000216	CcSEcCtD
Temsirolimus—Dyspnoea—Paclitaxel—kidney cancer	8.82e-06	0.000215	CcSEcCtD
Temsirolimus—Somnolence—Paclitaxel—kidney cancer	8.79e-06	0.000214	CcSEcCtD
Temsirolimus—Rash—Dactinomycin—kidney cancer	8.79e-06	0.000214	CcSEcCtD
Temsirolimus—Nausea—Sunitinib—kidney cancer	8.75e-06	0.000213	CcSEcCtD
Temsirolimus—Cough—Capecitabine—kidney cancer	8.68e-06	0.000212	CcSEcCtD
Temsirolimus—Dysuria—Doxorubicin—kidney cancer	8.61e-06	0.00021	CcSEcCtD
Temsirolimus—Neutropenia—Doxorubicin—kidney cancer	8.61e-06	0.00021	CcSEcCtD
Temsirolimus—Decreased appetite—Paclitaxel—kidney cancer	8.6e-06	0.00021	CcSEcCtD
Temsirolimus—Hypertension—Capecitabine—kidney cancer	8.59e-06	0.000209	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Doxorubicin—kidney cancer	8.55e-06	0.000208	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Paclitaxel—kidney cancer	8.54e-06	0.000208	CcSEcCtD
Temsirolimus—Fatigue—Paclitaxel—kidney cancer	8.53e-06	0.000208	CcSEcCtD
Temsirolimus—Diarrhoea—Vincristine—kidney cancer	8.52e-06	0.000208	CcSEcCtD
Temsirolimus—Pollakiuria—Doxorubicin—kidney cancer	8.5e-06	0.000207	CcSEcCtD
Temsirolimus—Asthenia—Gemcitabine—kidney cancer	8.48e-06	0.000207	CcSEcCtD
Temsirolimus—Myalgia—Capecitabine—kidney cancer	8.47e-06	0.000206	CcSEcCtD
Temsirolimus—Arthralgia—Capecitabine—kidney cancer	8.47e-06	0.000206	CcSEcCtD
Temsirolimus—Chest pain—Capecitabine—kidney cancer	8.47e-06	0.000206	CcSEcCtD
Temsirolimus—Pain—Paclitaxel—kidney cancer	8.46e-06	0.000206	CcSEcCtD
Temsirolimus—Constipation—Paclitaxel—kidney cancer	8.46e-06	0.000206	CcSEcCtD
Temsirolimus—Anxiety—Capecitabine—kidney cancer	8.44e-06	0.000206	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	8.41e-06	0.000205	CcSEcCtD
Temsirolimus—Pruritus—Gemcitabine—kidney cancer	8.36e-06	0.000204	CcSEcCtD
Temsirolimus—Weight decreased—Doxorubicin—kidney cancer	8.33e-06	0.000203	CcSEcCtD
Temsirolimus—Hyperglycaemia—Doxorubicin—kidney cancer	8.3e-06	0.000202	CcSEcCtD
Temsirolimus—Nausea—Dactinomycin—kidney cancer	8.28e-06	0.000202	CcSEcCtD
Temsirolimus—Pneumonia—Doxorubicin—kidney cancer	8.25e-06	0.000201	CcSEcCtD
Temsirolimus—Dizziness—Vincristine—kidney cancer	8.24e-06	0.000201	CcSEcCtD
Temsirolimus—Infestation NOS—Doxorubicin—kidney cancer	8.21e-06	0.0002	CcSEcCtD
Temsirolimus—Infestation—Doxorubicin—kidney cancer	8.21e-06	0.0002	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	8.13e-06	0.000198	CcSEcCtD
Temsirolimus—Oedema—Capecitabine—kidney cancer	8.12e-06	0.000198	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Paclitaxel—kidney cancer	8.09e-06	0.000197	CcSEcCtD
Temsirolimus—Diarrhoea—Gemcitabine—kidney cancer	8.08e-06	0.000197	CcSEcCtD
Temsirolimus—Renal failure—Doxorubicin—kidney cancer	8.07e-06	0.000197	CcSEcCtD
Temsirolimus—Infection—Capecitabine—kidney cancer	8.07e-06	0.000197	CcSEcCtD
Temsirolimus—Stomatitis—Doxorubicin—kidney cancer	8e-06	0.000195	CcSEcCtD
Temsirolimus—Urinary tract infection—Doxorubicin—kidney cancer	7.98e-06	0.000194	CcSEcCtD
Temsirolimus—Conjunctivitis—Doxorubicin—kidney cancer	7.98e-06	0.000194	CcSEcCtD
Temsirolimus—Nervous system disorder—Capecitabine—kidney cancer	7.96e-06	0.000194	CcSEcCtD
Temsirolimus—Thrombocytopenia—Capecitabine—kidney cancer	7.95e-06	0.000194	CcSEcCtD
Temsirolimus—Vomiting—Vincristine—kidney cancer	7.92e-06	0.000193	CcSEcCtD
Temsirolimus—Skin disorder—Capecitabine—kidney cancer	7.89e-06	0.000192	CcSEcCtD
Temsirolimus—Rash—Vincristine—kidney cancer	7.85e-06	0.000191	CcSEcCtD
Temsirolimus—Dermatitis—Vincristine—kidney cancer	7.85e-06	0.000191	CcSEcCtD
Temsirolimus—Haematuria—Doxorubicin—kidney cancer	7.82e-06	0.000191	CcSEcCtD
Temsirolimus—Body temperature increased—Paclitaxel—kidney cancer	7.82e-06	0.000191	CcSEcCtD
Temsirolimus—Abdominal pain—Paclitaxel—kidney cancer	7.82e-06	0.000191	CcSEcCtD
Temsirolimus—Headache—Vincristine—kidney cancer	7.8e-06	0.00019	CcSEcCtD
Temsirolimus—Epistaxis—Doxorubicin—kidney cancer	7.74e-06	0.000189	CcSEcCtD
Temsirolimus—Anorexia—Capecitabine—kidney cancer	7.74e-06	0.000189	CcSEcCtD
Temsirolimus—Sinusitis—Doxorubicin—kidney cancer	7.7e-06	0.000188	CcSEcCtD
Temsirolimus—Vomiting—Gemcitabine—kidney cancer	7.51e-06	0.000183	CcSEcCtD
Temsirolimus—Rash—Gemcitabine—kidney cancer	7.45e-06	0.000182	CcSEcCtD
Temsirolimus—Dermatitis—Gemcitabine—kidney cancer	7.44e-06	0.000181	CcSEcCtD
Temsirolimus—Headache—Gemcitabine—kidney cancer	7.4e-06	0.00018	CcSEcCtD
Temsirolimus—Nausea—Vincristine—kidney cancer	7.4e-06	0.00018	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Capecitabine—kidney cancer	7.4e-06	0.00018	CcSEcCtD
Temsirolimus—Rhinitis—Doxorubicin—kidney cancer	7.38e-06	0.00018	CcSEcCtD
Temsirolimus—Insomnia—Capecitabine—kidney cancer	7.34e-06	0.000179	CcSEcCtD
Temsirolimus—Pharyngitis—Doxorubicin—kidney cancer	7.31e-06	0.000178	CcSEcCtD
Temsirolimus—Hypersensitivity—Paclitaxel—kidney cancer	7.29e-06	0.000178	CcSEcCtD
Temsirolimus—Urinary tract disorder—Doxorubicin—kidney cancer	7.27e-06	0.000177	CcSEcCtD
Temsirolimus—Oedema peripheral—Doxorubicin—kidney cancer	7.26e-06	0.000177	CcSEcCtD
Temsirolimus—Connective tissue disorder—Doxorubicin—kidney cancer	7.24e-06	0.000176	CcSEcCtD
Temsirolimus—Dyspnoea—Capecitabine—kidney cancer	7.24e-06	0.000176	CcSEcCtD
Temsirolimus—Urethral disorder—Doxorubicin—kidney cancer	7.22e-06	0.000176	CcSEcCtD
Temsirolimus—Asthenia—Paclitaxel—kidney cancer	7.1e-06	0.000173	CcSEcCtD
Temsirolimus—Decreased appetite—Capecitabine—kidney cancer	7.06e-06	0.000172	CcSEcCtD
Temsirolimus—Nausea—Gemcitabine—kidney cancer	7.02e-06	0.000171	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Capecitabine—kidney cancer	7.01e-06	0.000171	CcSEcCtD
Temsirolimus—Fatigue—Capecitabine—kidney cancer	7e-06	0.000171	CcSEcCtD
Temsirolimus—Pruritus—Paclitaxel—kidney cancer	7e-06	0.000171	CcSEcCtD
Temsirolimus—Erythema multiforme—Doxorubicin—kidney cancer	6.96e-06	0.00017	CcSEcCtD
Temsirolimus—Pain—Capecitabine—kidney cancer	6.94e-06	0.000169	CcSEcCtD
Temsirolimus—Constipation—Capecitabine—kidney cancer	6.94e-06	0.000169	CcSEcCtD
Temsirolimus—Eye disorder—Doxorubicin—kidney cancer	6.88e-06	0.000168	CcSEcCtD
Temsirolimus—Cardiac disorder—Doxorubicin—kidney cancer	6.84e-06	0.000167	CcSEcCtD
Temsirolimus—Diarrhoea—Paclitaxel—kidney cancer	6.77e-06	0.000165	CcSEcCtD
Temsirolimus—Angiopathy—Doxorubicin—kidney cancer	6.68e-06	0.000163	CcSEcCtD
Temsirolimus—Immune system disorder—Doxorubicin—kidney cancer	6.65e-06	0.000162	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Capecitabine—kidney cancer	6.64e-06	0.000162	CcSEcCtD
Temsirolimus—Mediastinal disorder—Doxorubicin—kidney cancer	6.64e-06	0.000162	CcSEcCtD
Temsirolimus—Chills—Doxorubicin—kidney cancer	6.61e-06	0.000161	CcSEcCtD
Temsirolimus—Dizziness—Paclitaxel—kidney cancer	6.54e-06	0.000159	CcSEcCtD
Temsirolimus—Mental disorder—Doxorubicin—kidney cancer	6.45e-06	0.000157	CcSEcCtD
Temsirolimus—Abdominal pain—Capecitabine—kidney cancer	6.42e-06	0.000156	CcSEcCtD
Temsirolimus—Body temperature increased—Capecitabine—kidney cancer	6.42e-06	0.000156	CcSEcCtD
Temsirolimus—Erythema—Doxorubicin—kidney cancer	6.41e-06	0.000156	CcSEcCtD
Temsirolimus—Malnutrition—Doxorubicin—kidney cancer	6.41e-06	0.000156	CcSEcCtD
Temsirolimus—Vomiting—Paclitaxel—kidney cancer	6.29e-06	0.000153	CcSEcCtD
Temsirolimus—Dysgeusia—Doxorubicin—kidney cancer	6.28e-06	0.000153	CcSEcCtD
Temsirolimus—Rash—Paclitaxel—kidney cancer	6.24e-06	0.000152	CcSEcCtD
Temsirolimus—Dermatitis—Paclitaxel—kidney cancer	6.23e-06	0.000152	CcSEcCtD
Temsirolimus—Back pain—Doxorubicin—kidney cancer	6.2e-06	0.000151	CcSEcCtD
Temsirolimus—Headache—Paclitaxel—kidney cancer	6.2e-06	0.000151	CcSEcCtD
Temsirolimus—Hypersensitivity—Capecitabine—kidney cancer	5.98e-06	0.000146	CcSEcCtD
Temsirolimus—Anaemia—Doxorubicin—kidney cancer	5.93e-06	0.000144	CcSEcCtD
Temsirolimus—Nausea—Paclitaxel—kidney cancer	5.88e-06	0.000143	CcSEcCtD
Temsirolimus—Asthenia—Capecitabine—kidney cancer	5.82e-06	0.000142	CcSEcCtD
Temsirolimus—Pruritus—Capecitabine—kidney cancer	5.74e-06	0.00014	CcSEcCtD
Temsirolimus—Leukopenia—Doxorubicin—kidney cancer	5.74e-06	0.00014	CcSEcCtD
Temsirolimus—Cough—Doxorubicin—kidney cancer	5.6e-06	0.000136	CcSEcCtD
Temsirolimus—Convulsion—Doxorubicin—kidney cancer	5.56e-06	0.000135	CcSEcCtD
Temsirolimus—Diarrhoea—Capecitabine—kidney cancer	5.55e-06	0.000135	CcSEcCtD
Temsirolimus—Hypertension—Doxorubicin—kidney cancer	5.54e-06	0.000135	CcSEcCtD
Temsirolimus—Arthralgia—Doxorubicin—kidney cancer	5.46e-06	0.000133	CcSEcCtD
Temsirolimus—Myalgia—Doxorubicin—kidney cancer	5.46e-06	0.000133	CcSEcCtD
Temsirolimus—Chest pain—Doxorubicin—kidney cancer	5.46e-06	0.000133	CcSEcCtD
Temsirolimus—Anxiety—Doxorubicin—kidney cancer	5.44e-06	0.000133	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	5.42e-06	0.000132	CcSEcCtD
Temsirolimus—Dizziness—Capecitabine—kidney cancer	5.37e-06	0.000131	CcSEcCtD
Temsirolimus—Anaphylactic shock—Doxorubicin—kidney cancer	5.23e-06	0.000128	CcSEcCtD
Temsirolimus—Oedema—Doxorubicin—kidney cancer	5.23e-06	0.000128	CcSEcCtD
Temsirolimus—Infection—Doxorubicin—kidney cancer	5.2e-06	0.000127	CcSEcCtD
Temsirolimus—Vomiting—Capecitabine—kidney cancer	5.16e-06	0.000126	CcSEcCtD
Temsirolimus—Nervous system disorder—Doxorubicin—kidney cancer	5.13e-06	0.000125	CcSEcCtD
Temsirolimus—Thrombocytopenia—Doxorubicin—kidney cancer	5.12e-06	0.000125	CcSEcCtD
Temsirolimus—Rash—Capecitabine—kidney cancer	5.12e-06	0.000125	CcSEcCtD
Temsirolimus—Dermatitis—Capecitabine—kidney cancer	5.11e-06	0.000125	CcSEcCtD
Temsirolimus—Headache—Capecitabine—kidney cancer	5.09e-06	0.000124	CcSEcCtD
Temsirolimus—Skin disorder—Doxorubicin—kidney cancer	5.08e-06	0.000124	CcSEcCtD
Temsirolimus—Anorexia—Doxorubicin—kidney cancer	4.99e-06	0.000122	CcSEcCtD
Temsirolimus—Nausea—Capecitabine—kidney cancer	4.82e-06	0.000118	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Doxorubicin—kidney cancer	4.77e-06	0.000116	CcSEcCtD
Temsirolimus—Insomnia—Doxorubicin—kidney cancer	4.73e-06	0.000115	CcSEcCtD
Temsirolimus—Dyspnoea—Doxorubicin—kidney cancer	4.67e-06	0.000114	CcSEcCtD
Temsirolimus—Somnolence—Doxorubicin—kidney cancer	4.65e-06	0.000113	CcSEcCtD
Temsirolimus—Decreased appetite—Doxorubicin—kidney cancer	4.55e-06	0.000111	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Doxorubicin—kidney cancer	4.52e-06	0.00011	CcSEcCtD
Temsirolimus—Fatigue—Doxorubicin—kidney cancer	4.51e-06	0.00011	CcSEcCtD
Temsirolimus—Pain—Doxorubicin—kidney cancer	4.48e-06	0.000109	CcSEcCtD
Temsirolimus—Constipation—Doxorubicin—kidney cancer	4.48e-06	0.000109	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Doxorubicin—kidney cancer	4.28e-06	0.000104	CcSEcCtD
Temsirolimus—Abdominal pain—Doxorubicin—kidney cancer	4.14e-06	0.000101	CcSEcCtD
Temsirolimus—Body temperature increased—Doxorubicin—kidney cancer	4.14e-06	0.000101	CcSEcCtD
Temsirolimus—Hypersensitivity—Doxorubicin—kidney cancer	3.86e-06	9.4e-05	CcSEcCtD
Temsirolimus—Asthenia—Doxorubicin—kidney cancer	3.75e-06	9.15e-05	CcSEcCtD
Temsirolimus—Pruritus—Doxorubicin—kidney cancer	3.7e-06	9.02e-05	CcSEcCtD
Temsirolimus—Diarrhoea—Doxorubicin—kidney cancer	3.58e-06	8.73e-05	CcSEcCtD
Temsirolimus—Dizziness—Doxorubicin—kidney cancer	3.46e-06	8.43e-05	CcSEcCtD
Temsirolimus—Vomiting—Doxorubicin—kidney cancer	3.33e-06	8.11e-05	CcSEcCtD
Temsirolimus—Rash—Doxorubicin—kidney cancer	3.3e-06	8.04e-05	CcSEcCtD
Temsirolimus—Dermatitis—Doxorubicin—kidney cancer	3.3e-06	8.03e-05	CcSEcCtD
Temsirolimus—Headache—Doxorubicin—kidney cancer	3.28e-06	7.99e-05	CcSEcCtD
Temsirolimus—Nausea—Doxorubicin—kidney cancer	3.11e-06	7.58e-05	CcSEcCtD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	2.58e-06	0.000155	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GSTT1—kidney cancer	2.57e-06	0.000155	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ACHE—kidney cancer	2.57e-06	0.000155	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—RAF1—kidney cancer	2.57e-06	0.000154	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CA2—kidney cancer	2.57e-06	0.000154	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—RELA—kidney cancer	2.57e-06	0.000154	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	2.57e-06	0.000154	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—ERBB2—kidney cancer	2.55e-06	0.000153	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—ERBB2—kidney cancer	2.54e-06	0.000153	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CD4—kidney cancer	2.51e-06	0.000151	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MTOR—kidney cancer	2.51e-06	0.000151	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ANXA1—kidney cancer	2.51e-06	0.000151	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PSMD7—kidney cancer	2.51e-06	0.000151	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TSC1—kidney cancer	2.51e-06	0.000151	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CD4—kidney cancer	2.5e-06	0.000151	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ALAD—kidney cancer	2.5e-06	0.000151	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	2.49e-06	0.00015	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GPC3—kidney cancer	2.49e-06	0.00015	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KDR—kidney cancer	2.49e-06	0.00015	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTGS2—kidney cancer	2.49e-06	0.000149	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CDKN1B—kidney cancer	2.46e-06	0.000148	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	2.45e-06	0.000147	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ST3GAL2—kidney cancer	2.44e-06	0.000147	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	2.44e-06	0.000147	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—SCARB1—kidney cancer	2.44e-06	0.000146	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FLT1—kidney cancer	2.43e-06	0.000146	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	2.43e-06	0.000146	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CA2—kidney cancer	2.42e-06	0.000146	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS1—kidney cancer	2.41e-06	0.000145	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ALDH1A1—kidney cancer	2.39e-06	0.000144	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PSMD7—kidney cancer	2.36e-06	0.000142	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CDKN1B—kidney cancer	2.36e-06	0.000142	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	2.36e-06	0.000142	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ALAD—kidney cancer	2.36e-06	0.000142	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CDKN1B—kidney cancer	2.35e-06	0.000142	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—JUN—kidney cancer	2.34e-06	0.000141	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CTNNB1—kidney cancer	2.33e-06	0.00014	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ST3GAL2—kidney cancer	2.3e-06	0.000138	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—APC—kidney cancer	2.29e-06	0.000138	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KIT—kidney cancer	2.29e-06	0.000138	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PGK1—kidney cancer	2.29e-06	0.000138	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SLC5A3—kidney cancer	2.29e-06	0.000138	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PDHB—kidney cancer	2.28e-06	0.000137	CbGpPWpGaD
Temsirolimus—CYP3A4—Biological oxidations—POMC—kidney cancer	2.28e-06	0.000137	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PTEN—kidney cancer	2.27e-06	0.000136	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—TSC2—kidney cancer	2.26e-06	0.000136	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ALDH1A1—kidney cancer	2.25e-06	0.000135	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PAK1—kidney cancer	2.25e-06	0.000135	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—JUNB—kidney cancer	2.25e-06	0.000135	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—LDHB—kidney cancer	2.25e-06	0.000135	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—BCHE—kidney cancer	2.24e-06	0.000135	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CTNNB1—kidney cancer	2.22e-06	0.000134	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—SLC5A5—kidney cancer	2.21e-06	0.000133	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CRABP1—kidney cancer	2.19e-06	0.000132	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—POMC—kidney cancer	2.18e-06	0.000131	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PTEN—kidney cancer	2.18e-06	0.000131	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTEN—kidney cancer	2.17e-06	0.00013	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SLC5A3—kidney cancer	2.16e-06	0.00013	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PGK1—kidney cancer	2.16e-06	0.00013	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—BRAF—kidney cancer	2.16e-06	0.00013	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CCBL1—kidney cancer	2.15e-06	0.000129	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—SLC2A1—kidney cancer	2.14e-06	0.000129	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	2.14e-06	0.000128	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—LDHB—kidney cancer	2.12e-06	0.000127	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HIF1A—kidney cancer	2.09e-06	0.000126	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TSC2—kidney cancer	2.09e-06	0.000125	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ITPR2—kidney cancer	2.04e-06	0.000123	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	2.02e-06	0.000121	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KIT—kidney cancer	1.99e-06	0.00012	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	1.96e-06	0.000118	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CA9—kidney cancer	1.95e-06	0.000117	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—MAPK3—kidney cancer	1.94e-06	0.000116	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	1.92e-06	0.000116	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PPAT—kidney cancer	1.86e-06	0.000112	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.86e-06	0.000112	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTT1—kidney cancer	1.86e-06	0.000112	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ACHE—kidney cancer	1.86e-06	0.000112	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MAPK3—kidney cancer	1.85e-06	0.000111	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—MAPK1—kidney cancer	1.84e-06	0.000111	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KIT—kidney cancer	1.84e-06	0.000111	CbGpPWpGaD
Temsirolimus—MTOR—Disease—APC—kidney cancer	1.84e-06	0.000111	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IGF2—kidney cancer	1.84e-06	0.000111	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDH1—kidney cancer	1.84e-06	0.00011	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CA9—kidney cancer	1.84e-06	0.00011	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDKN2B—kidney cancer	1.83e-06	0.00011	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	1.82e-06	0.000109	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MYC—kidney cancer	1.8e-06	0.000108	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—RAF1—kidney cancer	1.8e-06	0.000108	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—RELA—kidney cancer	1.79e-06	0.000108	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GSTP1—kidney cancer	1.78e-06	0.000107	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ERBB2—kidney cancer	1.78e-06	0.000107	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IGF1R—kidney cancer	1.78e-06	0.000107	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MAPK1—kidney cancer	1.76e-06	0.000106	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—SCARB1—kidney cancer	1.76e-06	0.000106	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MTOR—kidney cancer	1.76e-06	0.000106	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS1—kidney cancer	1.74e-06	0.000105	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KRAS—kidney cancer	1.74e-06	0.000105	CbGpPWpGaD
Temsirolimus—MTOR—Disease—BRAF—kidney cancer	1.73e-06	0.000104	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—FH—kidney cancer	1.73e-06	0.000104	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—APRT—kidney cancer	1.73e-06	0.000104	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PSMD7—kidney cancer	1.71e-06	0.000103	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ABCB1—kidney cancer	1.69e-06	0.000102	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KRAS—kidney cancer	1.67e-06	0.000101	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	1.67e-06	0.0001	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KRAS—kidney cancer	1.66e-06	0.0001	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CRABP1—kidney cancer	1.66e-06	9.95e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CDKN1B—kidney cancer	1.65e-06	9.91e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GSTM1—kidney cancer	1.64e-06	9.85e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GPC3—kidney cancer	1.63e-06	9.78e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—BCHE—kidney cancer	1.62e-06	9.74e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL2—kidney cancer	1.61e-06	9.7e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1.61e-06	9.7e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—SLC5A5—kidney cancer	1.6e-06	9.62e-05	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PIK3CA—kidney cancer	1.6e-06	9.62e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CA2—kidney cancer	1.58e-06	9.52e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CCND1—kidney cancer	1.57e-06	9.46e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—JUN—kidney cancer	1.57e-06	9.44e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—RAF1—kidney cancer	1.57e-06	9.41e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CRABP1—kidney cancer	1.56e-06	9.38e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—RELA—kidney cancer	1.56e-06	9.37e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CTNNB1—kidney cancer	1.56e-06	9.36e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CYP1A1—kidney cancer	1.55e-06	9.34e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ERBB2—kidney cancer	1.55e-06	9.31e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—SLC2A1—kidney cancer	1.55e-06	9.29e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ALAD—kidney cancer	1.54e-06	9.27e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ITPR2—kidney cancer	1.54e-06	9.25e-05	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PIK3CA—kidney cancer	1.54e-06	9.23e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PIK3CA—kidney cancer	1.53e-06	9.19e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CD4—kidney cancer	1.53e-06	9.17e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTEN—kidney cancer	1.52e-06	9.13e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.51e-06	9.05e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.47e-06	8.85e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HIF1A—kidney cancer	1.46e-06	8.8e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TSC2—kidney cancer	1.46e-06	8.78e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ITPR2—kidney cancer	1.45e-06	8.72e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—RAF1—kidney cancer	1.45e-06	8.69e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDKN1B—kidney cancer	1.43e-06	8.62e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERBB2—kidney cancer	1.43e-06	8.6e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PGK1—kidney cancer	1.41e-06	8.48e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.41e-06	8.48e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CD4—kidney cancer	1.41e-06	8.47e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ACHE—kidney cancer	1.4e-06	8.44e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTT1—kidney cancer	1.4e-06	8.44e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL2—kidney cancer	1.4e-06	8.44e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KDR—kidney cancer	1.4e-06	8.42e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTGS2—kidney cancer	1.4e-06	8.4e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—LDHB—kidney cancer	1.38e-06	8.32e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—VEGFA—kidney cancer	1.37e-06	8.24e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—JUN—kidney cancer	1.37e-06	8.21e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CTNNB1—kidney cancer	1.35e-06	8.15e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SCARB1—kidney cancer	1.33e-06	7.99e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CDKN1B—kidney cancer	1.32e-06	7.96e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTT1—kidney cancer	1.32e-06	7.95e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ACHE—kidney cancer	1.32e-06	7.95e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PTEN—kidney cancer	1.32e-06	7.94e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS1—kidney cancer	1.32e-06	7.91e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MAPK3—kidney cancer	1.3e-06	7.8e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PSMD7—kidney cancer	1.29e-06	7.75e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—APC—kidney cancer	1.29e-06	7.75e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KIT—kidney cancer	1.29e-06	7.75e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTP1—kidney cancer	1.29e-06	7.75e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MYC—kidney cancer	1.26e-06	7.58e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SCARB1—kidney cancer	1.25e-06	7.53e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CTNNB1—kidney cancer	1.25e-06	7.52e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS1—kidney cancer	1.24e-06	7.45e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MAPK1—kidney cancer	1.23e-06	7.42e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—POMC—kidney cancer	1.23e-06	7.38e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—BCHE—kidney cancer	1.22e-06	7.35e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ABCB1—kidney cancer	1.22e-06	7.34e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTEN—kidney cancer	1.22e-06	7.33e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PSMD7—kidney cancer	1.22e-06	7.31e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—BRAF—kidney cancer	1.21e-06	7.29e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SLC5A5—kidney cancer	1.21e-06	7.26e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CA9—kidney cancer	1.2e-06	7.21e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTM1—kidney cancer	1.18e-06	7.12e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SLC2A1—kidney cancer	1.17e-06	7.01e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KRAS—kidney cancer	1.17e-06	7.01e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—POMC—kidney cancer	1.16e-06	6.96e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—BCHE—kidney cancer	1.15e-06	6.93e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SLC5A5—kidney cancer	1.14e-06	6.84e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MAPK3—kidney cancer	1.13e-06	6.78e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP1A1—kidney cancer	1.12e-06	6.75e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	1.11e-06	6.69e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SLC2A1—kidney cancer	1.1e-06	6.61e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MAPK1—kidney cancer	1.07e-06	6.45e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PIK3CA—kidney cancer	1.07e-06	6.44e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MAPK3—kidney cancer	1.04e-06	6.26e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—kidney cancer	1.04e-06	6.23e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CRABP1—kidney cancer	1.02e-06	6.13e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KRAS—kidney cancer	1.01e-06	6.1e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MYC—kidney cancer	1.01e-06	6.09e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RAF1—kidney cancer	1.01e-06	6.08e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RELA—kidney cancer	1.01e-06	6.06e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ERBB2—kidney cancer	1e-06	6.02e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MAPK1—kidney cancer	9.91e-07	5.96e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTP1—kidney cancer	9.73e-07	5.85e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ITPR2—kidney cancer	9.48e-07	5.7e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KRAS—kidney cancer	9.36e-07	5.63e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PIK3CA—kidney cancer	9.32e-07	5.6e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDKN1B—kidney cancer	9.27e-07	5.57e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS2—kidney cancer	9.24e-07	5.56e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTP1—kidney cancer	9.17e-07	5.51e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL2—kidney cancer	9.07e-07	5.46e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTM1—kidney cancer	8.94e-07	5.37e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CCND1—kidney cancer	8.85e-07	5.32e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—JUN—kidney cancer	8.83e-07	5.31e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CTNNB1—kidney cancer	8.76e-07	5.27e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ABCB1—kidney cancer	8.68e-07	5.22e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTT1—kidney cancer	8.65e-07	5.2e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ACHE—kidney cancer	8.65e-07	5.2e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PIK3CA—kidney cancer	8.6e-07	5.17e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTEN—kidney cancer	8.54e-07	5.13e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP1A1—kidney cancer	8.48e-07	5.1e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTM1—kidney cancer	8.43e-07	5.07e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—POMC—kidney cancer	8.38e-07	5.03e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SCARB1—kidney cancer	8.19e-07	4.92e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS1—kidney cancer	8.1e-07	4.87e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTEN—kidney cancer	8.06e-07	4.84e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP1A1—kidney cancer	7.99e-07	4.8e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PSMD7—kidney cancer	7.95e-07	4.78e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—VEGFA—kidney cancer	7.71e-07	4.64e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—BCHE—kidney cancer	7.53e-07	4.53e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC5A5—kidney cancer	7.44e-07	4.47e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAPK3—kidney cancer	7.3e-07	4.39e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC2A1—kidney cancer	7.19e-07	4.32e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MYC—kidney cancer	7.1e-07	4.27e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAPK1—kidney cancer	6.94e-07	4.17e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS2—kidney cancer	6.68e-07	4.02e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KRAS—kidney cancer	6.56e-07	3.94e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—POMC—kidney cancer	6.32e-07	3.8e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CA—kidney cancer	6.02e-07	3.62e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTP1—kidney cancer	5.99e-07	3.6e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—POMC—kidney cancer	5.96e-07	3.58e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—kidney cancer	5.83e-07	3.5e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTEN—kidney cancer	5.83e-07	3.5e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CA—kidney cancer	5.69e-07	3.42e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ABCB1—kidney cancer	5.67e-07	3.41e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTM1—kidney cancer	5.51e-07	3.31e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP1A1—kidney cancer	5.22e-07	3.14e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS2—kidney cancer	5.04e-07	3.03e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS2—kidney cancer	4.75e-07	2.86e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTEN—kidney cancer	4.4e-07	2.64e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTEN—kidney cancer	4.14e-07	2.49e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CA—kidney cancer	4.11e-07	2.47e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—POMC—kidney cancer	3.89e-07	2.34e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS2—kidney cancer	3.11e-07	1.87e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CA—kidney cancer	3.1e-07	1.86e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CA—kidney cancer	2.92e-07	1.76e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTEN—kidney cancer	2.71e-07	1.63e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.91e-07	1.15e-05	CbGpPWpGaD
